Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Viral Infections

A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients

Bone Marrow Transplantation volume 28, pages 485–490 (2001)Cite this article

Abstract

Preemptive antiviral therapy is often employed for CMV prevention following allogeneic BMT. Two common strategies are a screening bronchoscopy for CMV post-BMT or regular CMV antigenemia testing with ganciclovir administration for a positive result. In a randomised trial, we prospectively compared the efficacy of these two preemptive strategies. Consecutive patients were randomised to either a bronchoscopy for CMV on day 35 post BMT or weekly CMV antigenemia testing. If the bronchoscopy was positive for CMV, patients received preemptive ganciclovir for 8–10 weeks. If the antigenemia was positive for CMV, patients received a minimum of 2 weeks of preemptive ganciclovir. The primary endpoint was the development of active CMV disease. One hundred and eighteen allogeneic BMT patients were enrolled (60 in the antigenemia arm and 58 in the bronchoscopy arm). The two groups were comparable with respect to baseline demographic data, underlying disease, conditioning regimen, and immunosuppression. Active CMV disease developed in 7/58 (12.1%) patients in the bronchoscopy arm vs 1/60 patients (1.7%) in the CMV antigenemia arm (P = 0.022). Based on the screening test, 13.8% of patients received preemptive ganciclovir in the bronchoscopy arm vs 48.3% of patients in the antigenemia arm (P < 0.001). There was no significant difference in the rate of graft-versus-host disease, bacteremia, invasive fungal infections or mortality between the two groups. Preemptive therapy based on regular CMV antigenemia monitoring is superior to screening bronchoscopy for the prevention of CMV disease after allogeneic BMT. Bone Marrow Transplantation (2001) 28, 485–490.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Prentice HG, Kho P . Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplantation Bone Marrow Transplant 1997 19: 135–142

    Article  CAS  PubMed  Google Scholar 

  2. Avery RK, Adal KA, Longworth DL, Bolwell BJ . A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and preemptive therapy Bone Marrow Transplant 2000 26: 763–767

    Article  CAS  PubMed  Google Scholar 

  3. Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant Ann Intern Med 1993 118: 173–178

    Article  CAS  PubMed  Google Scholar 

  4. Winston DJ, Ho WG, Bartoni RN et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients Ann Intern Med 1993 118: 179–184

    Article  CAS  PubMed  Google Scholar 

  5. Nguyen Q, Champlin R, Giralt S et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients Clin Infect Dis 1999 28: 618–623

    Article  CAS  PubMed  Google Scholar 

  6. Salzberger B, Bowden RA, Fackman RC et al. Neutropenia in allogeneic marrow transplant recipients ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome Blood 1997 90: 2502–2508

    CAS  PubMed  Google Scholar 

  7. Schmidt GM, Horak DA, Niland JC et al. A randomised controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants New Engl J Med 1991 324: 1005–1011

    Article  CAS  PubMed  Google Scholar 

  8. Reddy V, Hao Y, Lipton J et al. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged preemptive ganciclovir therapy J Clin Virol 1999 13: 149–159

    Article  CAS  PubMed  Google Scholar 

  9. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation New Engl J Med 1991 325: 1601–1607

    Article  CAS  PubMed  Google Scholar 

  10. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study Blood 1996 88: 4063–4071

    CAS  PubMed  Google Scholar 

  11. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation Blood 1995 86: 2815–2820

    CAS  PubMed  Google Scholar 

  12. Ljungman P, Plotkin SA . Workshop on CMV disease. Definitions, clinical severity scores, and new syndromes. Proceedings from the 5th International Cytomegalovirus Conference May 21–24, 1995, Stockholm, Sweden Scan J Infect Dis Suppl 1995 99: 87–89

    Google Scholar 

  13. Van der Bij W, Torensma R, Van Son WJ et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes J Med Virol 1988 25: 179–188

    Article  CAS  PubMed  Google Scholar 

  14. Mazzulli T, Wood S, Chua R, Walmsley S . Evaluation of the Digene Hybrid Capture System for detection and quantification of human cytomegalovirus viremia in human immunodeficiency virus-infected patients J Clin Microbiol 1996 34: 2959–2962

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Li CR, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis Blood 1994 83: 1971–1979

    CAS  PubMed  Google Scholar 

  16. Humar A, Wood S, Lipton J et al. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation Bone Marrow Transplant 1999 23: 45–51

    Article  CAS  PubMed  Google Scholar 

  17. Hebart H, Muller C, Loffler J et al. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation Bone Marrow Transplant 1996 17: 861–868

    CAS  PubMed  Google Scholar 

  18. Boeckh M, Gallez-Hawkins GM, Myerson D et al. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture Transplantation 1997 64: 108–113

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Informed consent was obtained from all patients for participation in the study. This work was funded by a grant from the Physicians Services Incorporated.

Author information

Authors and Affiliations

  1. Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Canada

    A Humar

  2. Department of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Canada

    J Lipton & H Messner

  3. Department of Laboratory Medicine and Pathobiology, Mount Sinai Hospital, University of Toronto, Toronto, Canada

    S Welsh, G Moussa & T Mazzulli

Authors
  1. A Humar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Welsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Moussa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Messner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Mazzulli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Humar, A., Lipton, J., Welsh, S. et al. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Bone Marrow Transplant 28, 485–490 (2001). https://doi.org/10.1038/sj.bmt.1703178

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703178

Keywords

This article is cited by

Search

Advanced search

Quick links